ArticleClinical case reports2018
Frontline brentuximab vedotin in breast implant-associated anaplastic large-cell lymphoma.
Article in Clinical case reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Implant replacement and anaplastic large cell lymphoma associated with breast implants: a quantitative analysis.Frontiers in oncology · 2023Pooled it
- UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma on behalf of the Medicines and Healthcare products Regulatory Agency Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group.British journal of haematology · 2021Guideline
- Neoadjuvant Immunotherapy and De-escalation of Surgery in Locally Advanced Breast Implant-associated Anaplastic Large Cell Lymphoma.Archives of plastic surgery · 2025Article
- CD30 Regulation of IL-13-STAT6 Pathway in Breast Implant-Associated Anaplastic Large Cell Lymphoma.Aesthetic surgery journal · 2023Article
- Primary Lymphomas of the Breast: A Review.JPRAS open · 2022Article
- An Unusual Case of Breast Implant-Associated Anaplastic Large Cell Lymphoma.Case reports in hematology · 2022Article
- The Successful Use of Neo Adjuvant Brentuximab Vedotin in the Treatment of BIA-ALCL.HemaSphere · 2020Article
- Breast Implant-associated Anaplastic Large Cell Lymphoma: A Review with Emphasis on the Role of Brentuximab Vedotin.Journal of cellular immunology · 2020Article
- Cell of Origin and Immunologic Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large-Cell Lymphoma.The American journal of pathology · 2020Review
- Brentuximab vedotin as frontline treatment for HIV-related extracavitary primary effusion lymphoma.International journal of hematology · 2019Article
- Brentuximab vedotin as monotherapy for unresectable breast implant-associated anaplastic large cell lymphoma.Clinical case reports · 2019Article
- Is breast implant-associated anaplastic large cell lymphoma a hazard of breast implant surgery?Open biology · 2019Review
- Synchronous Breast Implant-associated Anaplastic Large Cell Lymphoma and Invasive Carcinoma: Genomic Profiling and Management Implications.Plastic and reconstructive surgery. Global open · 2019Article
- The Cellular Origins of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): Implications for Immunogenesis.Aesthetic surgery journal · 2019Article
- Article
- Frontline brentuximab vedotin in breast implant-associated anaplastic large-cell lymphoma.Clinical case reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a woman who developed BIA-ALCL 9 years after saline implant placement. The lymphoma manifested as a mass lesion associated with axillary lymphadenopathy. She was successfully treated with brentuximab vedotin with minimal toxicity. Brentuximab vedotin may be a promising frontline therapeutic modality for patients with BIA-ALCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.